Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Beruzatatug Pelitecan · BNT326

Antibody-drug conjugate · Cytotoxic, directed at HER3 (ErbB3) (ERBB3) and DNA topoisomerase I (TOP1) · developed by BioNTech

Phase 1/2 Most advanced trial
BNTX Developer
1 Registered trials

What is Beruzatatug Pelitecan?

Beruzatatug pelitecan is an antibody-drug conjugate made of an IgG1 antibody that binds HER3 (ErbB3) on tumor cells, linked by a protease-cleavable tripeptide linker to the topoisomerase I inhibitor YL0010014. After cleavage in the tumor microenvironment, the released payload stabilizes topoisomerase I-DNA cleavable complexes, causing DNA breaks and apoptosis. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BNT326
Drug type
Antibody-drug conjugate
Targets
HER3 (ErbB3) (ERBB3), DNA topoisomerase I (TOP1)
Mechanism
Cytotoxic, directed at HER3 (ErbB3) (ERBB3) and DNA topoisomerase I (TOP1)
Pathways
DNA replication inhibition, apoptosis
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
DAW7F54AQE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07070232 Phase 1/2 Advanced Solid Tumor Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on ERBB3 / TOP1

More from BioNTech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind Beruzatatug Pelitecan

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.